Konzept der unterstützten Sekundärprävention nach Schlaganfall

Zusammenfassung

Hintergrund: Patienten mit einem akuten Schlaganfall oder einer transitorischen ischämischen Attacke (TIA) haben ein hohes Risiko für neue vaskuläre Ereignisse. Mehrere evidenzbasierte Strategien zur Sekundärprävention sind verfügbar, vermutlich aber noch nicht ausreichend genutzt. Bislang wurden Unterstützungsprogramme, die auf eine multifaktorielle Modifikation der Risikofaktoren abzielen, zwar bei anderen Erkrankungen wie Diabetes mellitus oder koronarer Herzkrankheit aber noch nicht beim Schlaganfall in prospektiven kontrollierten Studien untersucht. INSPiRE-TMS ist eine multizentrische, randomisierte offene Interventionsstudie für intensivierte Sekundärprävention nach leichtem Schlaganfall und TIA. Methoden: An den teilnehmenden Zentren werden geeignete Patienten mit TIA oder leichtem Schlaganfall rekrutiert und 1:1 in einen Interventions- und einen Kontrollarm randomisiert. 2 082 Patienten sollen eingeschlossen werden. Das Unterstützungsprogramm beinhaltet die Messung der kardiovaskulären Risikofaktoren und Feedback, das Monitoring der Adhärenz, Beratung bezüglich einer Lebensstiländerung und die aktive Einbeziehung der Angehörigen. Standardisiertes „Motivational Interviewing“ soll die Patienten motivieren und in dieser Motivation stärken. Primäres Studienziel ist die Reduktion vaskulärer Ereignisse (Hirninfarkt, Myokardinfarkt, vaskulärer Tod). Die Beobachtungszeit soll für jeden Patienten mindestens zwei Jahre betragen. Diskussion: Aufgrund des hohen Rezidivrisikos nach einem akuten Schlaganfall und zugleich bekannten effektiven sekundärpräventiven Strategien, hat die INSPiRE-TMS-Intervention das Potenzial, zu einer relevanten Reduktion von erneuten vaskulären Ereignissen und einer verlängerten ereignisfreien Überlebenszeit zu führen. Die Studie wird mit zu der Entscheidung beitragen, ob ein Programm zur intensivierten Sekundärprävention nach Schlaganfall in die Regelversorgung übernommen werden sollte. Zusätzlich wird die Kosteneffektivität mitbeurteilt.

Summary

Background: Patients with recent stroke or transient ischemic attack (TIA) have a high risk for recurrent vascular events. Multiple evidence-based strategies in secondary prevention are recommended but presumably not sufficiently utilized. Support programmes targeting vascular risk factors have been evaluated in prospective randomized trials for other diseases like diabetes mellitus or coronary heart disease. However, no such support programme has been investigated in patients after stroke. INSPiRE-TMS is a multicentre, prospective and randomized intervention trial for intensified secondary prevention after TIA or minor stroke. Methods: Patients with recent TIA or minor stroke are randomized in a 1:1 manner into an intervention (usual care plus support programme) and a control (usual care) arm. The trial will include 2 082 patients. The support programme consists of the following components: measurement of the vascular risk parameters, monitoring of the adherence to medication, counselling concerning lifestyle-modification and involvement of the relatives. Using standardized “motivational interviewing”, the patients’ motivation shall be consolidated and strengthened. Patients will be followed up for at least 2 years. Discussion: Through systematic implementation of available evidence-based strategies in secondary prevention, INSPiRE-TMS has the potential to reduce recurrent vascular events and to extend the event-free survival time in acute stroke patients. As a result, it will contribute to the decision, whether an intensified secondary prevention support programme after stroke should be implemented into regular care.

Schlüsselwörter

TIA - Schlaganfall - Sekundärprävention - Interventionsstudie

Keywords

TIA - stroke secondary prevention - intervention trial

• Literatur

• 1 Bhatt DL, Steg PG, Ohman EM. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9.
• 2 Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
• 3 Sacco RL, Diener HC, Yusuf S. et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-51.
• 4 Amarenco P, Bogousslavsky J, Callahan A. et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.
• 5 Rother J, Alberts MJ, Touze E. et al. Risk factor profile and management of cerebrovascular patients in the REACH Registry. Cerebrovasc Dis 2008; 25: 366-74.
• 6 Alberts MJ, Bhatt DL, Mas JL. et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J 2009; 30: 2318-26.
• 7 Bushnell CD, Olson DM, Zhao X. et al. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology 2011; 77: 1182-90.
• 8 Wolf-Maier K, Cooper RS, Banegas JR. et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-9.
• 9 Leistner S, Benik S, Laumeier I. et al. Secondary Prevention after Minor Stroke and TIA – Usual care and development of a support program. Plos-One. 2012 December 17 DOI:
• 10 Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
• 11 Giannuzzi P, Temporelli PL, Marchioli R. et al. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Intern Med 2008; 168: 2194-204.
• 12 Green BB, Cook AJ, Ralston JD. et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA 2008; 299: 2857-67.
• 13 Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91.
• 14 Moreno Palanco MA, Ciria de Pablo C, Ibanez Sanz P, Sanchez Luis C, Pizarro Portillo A, Suarez Fernandez C. [Cardiovascular morbimortality reduction after an acute cardiovascular event through multifactorial and intensive cardiovascular risk factors management (MIRVAS project)]. Med Clin (Barc) 2007; 129: 241-6.
• 15 Chimowitz MI, Lynn MJ, Derdeyn CP. et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365: 993-1003.
• 16 Chimowitz MI, Lynn MJ, Howlett-Smith H. et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305-16.
• 17 Joubert J, Davis SM, Hankey GJ. et al. ICARUSS, the Integrated Care for the Reduction of Secondary Stroke trial: rationale and design of a randomized controlled trial of a multimodal intervention to prevent recurrent stroke in patients with a recent cerebrovascular event, ACTRN 12611000264987. Int J Stroke 2015; 10: 773-7.
• 18 Leistner S, Michelson G, Laumeier I. et al. Intensified secondary prevention intending a reduction of recurrent events in TIA and minor stroke patients (INSPiRE-TMS): a protocol for a randomised controlled trial. BMC Neurol 2013; 13: 11.
• 19 Intensified Secondary Prevention Intending a Reduction of Recurrent Events in TIA and Minor Stroke Patients (INSPiRE-TMS). Clinical-Trials.gov. 2012 http://clinicaltrials.gov/ct2/show/NCT01586702?term=audebert&rank=2
• 20 Adams Jr. HP, Bendixen BH, Kappelle LJ. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
• 21 Miller WR. Motivational interviewing: Preparing people for change. New York: Guilford Press; 2002
• 22 Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-73.
• 23 Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 2011; 42: 1489-94.
• 24 Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342: 1255-62.
• 25 Barnett HJ, Taylor DW, Eliasziw M. et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998; 339: 1415-25.
• 26 Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901-6.
• 27 Lawrence M, Kerr S, Watson H, Paton G, Ellis G. An exploration of lifestyle beliefs and lifestyle behaviour following stroke: findings from a focus group study of patients and family members. BMC Fam Pract 2010; 11: 97.
• 28 Rothwell PM, Giles MF, Chandratheva A. et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007; 370: 1432-42.
• 29 Lavallee PC, Meseguer E, Abboud H. et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol 2007; 6: 953-60.
• 30 Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004; 291: 1238-45.
• 31 PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attach or Stroke Trial. 2012 http://clinical-trials.gov/ct2/show/NCT01020851?term=NCT+01020851&rank=1
• 32 The Post Stroke Preventive Trial (PREVENT). A RCT Nested in a Cohort Study. http://clinical-trials.gov/ct2/show/NCT00253097?term=NCT+00253097&rank=1
• 33 Tailored Intervention to Improve Patient Adherence to Secondary Stroke Prevention Medication (NCT01684176). 2012 http://clinicaltrials.gov/ct2/show/NCT01684176?term=Tailored+Inter-vention+to+Improve+Patient+Adherence+to+Secondary+Stroke+Prevention+Medication&rank=1
• 34 Reducing disabiility in older Australians through secondary stroke prevention (ACTRN12611000264987). 2011 http://www.anzctr.org.au/trial_view.aspx?ID=336582
• 35 A cluster randomized controlled trial to evaluate a disease and care-management intervention for cardiovascular prevention in primary care: The Raffaello Project. (ACTRN12611000813987). 2011 http://www.anzctr.org.au/trial_view.aspx?ID=343284
• 36 Rochette A, Korner-Bitensky N, Bishop D. et al. Study protocol of the YOU CALL – WE CALL TRIAL: impact of a multimodal support intervention after a „mild“ stroke. BMC Neurol 2010; 10: 3.
• 37 Development of a Stroke Prevention Program for an Underserved Minority Community (NCT01071408). 2010 http://clinicaltrials.gov/ct2/show/NCT01071408?term=Development+of+a+Stroke+Prevention+Program+for+an+Underserved+Minority+Community&rank=1
• 38 Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack (PREVENTION) (NCT00931788). 2009 http://clinical-trials.gov/ct2/show/NCT00931788?term=Preventing+Recurrent+Vascular+Events+in+Patients+With+Stroke+or+Transient+Ischemic+Attack&rank=1
• 39 STroke inpatient secOndary Prevention: current status and continuous care improvement (ISRCTN17207064). 2007 http://www.controlled-trials.com/ISRCTN17207064/secondary+prevention
• 40 IMproving the PRevention Of Vascular Events after stroke or transient ischemic attack, the IMPROVE pilot trial (ISRCTN63816609). 2012 http://www.controlled-trials.com/ISRCTN63816609/secondary+prevention